Institutional shares held 61 Million
609K calls
400K puts
Total value of holdings $2.26B
$22.5M calls
$14.8M puts
Market Cap $6.19B
167,403,008 Shares Out.
Institutional ownership 36.45%
# of Institutions 234


Latest Institutional Activity in LEGN

Top Purchases

Q2 2025
Deerfield Management Company, L.P. (Series C) Shares Held: 2.96M ($110M)
Q2 2025
Balyasny Asset Management LLC Shares Held: 948K ($35.1M)
Q2 2025
Canada Pension Plan Investment Board Shares Held: 445K ($16.5M)
Q2 2025
Stem Point Capital LP Shares Held: 270K ($9.99M)
Q2 2025
Logos Global Management LP Shares Held: 250K ($9.25M)

Top Sells

Q2 2025
Price T Rowe Associates Inc Shares Held: 800K ($29.6M)
Q2 2025
Invesco Ltd. Shares Held: 16.8K ($623K)
Q2 2025
Massachusetts Financial Services CO Shares Held: 446K ($16.5M)
Q2 2025
Mirae Asset Global Investments Co., Ltd. Shares Held: 14.9K ($553K)
Q2 2025
Morgan Stanley Shares Held: 518K ($19.2M)

About LEGN

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.


Insider Transactions at LEGN

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on LEGN

Follow Legend Biotech Corp and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LEGN shares.

Notify only if

Insider Trading

Get notified when an Legend Biotech Corp insider buys or sells LEGN shares.

Notify only if

News

Receive news related to Legend Biotech Corp

Track Activities on LEGN